Gene · 8205
Papers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 2,064
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. | Int J Gen Med | 2022 | 35846794 | PubTator, text mining | PubMed |
| Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study. | Clin Drug Investig | 2022 | 35838880 | PubTator, text mining | PubMed |
| WNT signaling and cancer stemness. | Essays Biochem | 2022 | 35837811 | PubTator, text mining | PubMed |
| Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. | Eur J Med Chem | 2022 | 35834904 | PubTator, text mining | PubMed |
| Bispecific antibodies for the treatment of neuroblastoma. | Pharmacol Ther | 2022 | 35830901 | PubTator, text mining | PubMed |
| DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer. | J Exp Clin Cancer Res | 2022 | 35820928 | PubTator, text mining | PubMed |
| An Eleven-microRNA Signature Related to Tumor-Associated Macrophages Predicts Prognosis of Breast Cancer. | Int J Mol Sci | 2022 | 35805995 | PubTator, text mining | PubMed |
| Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina. | Cancers (Basel) | 2022 | 35805057 | PubTator, text mining | PubMed |
| eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma. | J Transl Med | 2022 | 35794622 | PubTator, text mining | PubMed |
| Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo. | Ren Fail | 2022 | 35793478 | PubTator, text mining | PubMed |
| Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. | Eur J Nucl Med Mol Imaging | 2022 | 35788730 | PubTator, text mining | PubMed |
| Prospective dietary polyunsaturated fatty acid intake is associated with trajectories of fatty liver disease: an 8 year follow-up study from adolescence to young adulthood. | Eur J Nutr | 2022 | 35780424 | PubTator, text mining | PubMed |
| Clinical significance and prospective molecular mechanism of NUF2 in gastric cancer exploration: A comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases. | Medicine (Baltimore) | 2022 | 35777029 | PubTator, text mining | PubMed |
| Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities. | Front Pharmacol | 2022 | 35774605 | PubTator, text mining | PubMed |
| Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. | Front Cell Dev Biol | 2022 | 35774228 | PubTator, text mining | PubMed |
| First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. | Invest New Drugs | 2022 | 35767205 | PubTator, text mining | PubMed |
| Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma. | Oncology | 2022 | 35760058 | PubTator, text mining | PubMed |
| Harnessing the Power of Health Systems and Networks for Antimicrobial Stewardship. | Clin Infect Dis | 2022 | 35758333 | PubTator, text mining | PubMed |
| Human Neutrophils Present Mild Activation by Zika Virus But Reduce the Infection of Susceptible Cells. | Front Immunol | 2022 | 35747137 | PubTator, text mining | PubMed |
| Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. | Biomolecules | 2022 | 35740975 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8205/papers?page=32